Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to create an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. The first CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a highly marketing image in the Uptick Newswire employment interview that I came away with an inadequate impression of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, however, the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and associated intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) and also the first brand new drug program endorsement ($5 million), and also royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and multiple therapies, it’s this single therapies in addition to a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Could it all be smoke cigarettes and mirrors? That is a question I have been asking myself through the really start of the interest of mine in this company. Judging by the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *